Artur Aira - Cellink AB Sr Bioprinting
| CLLKF Stock | USD 3.65 0.33 8.29% |
Insider
Artur Aira is Sr Bioprinting of Cellink AB
| Age | 56 |
| Phone | 46 7 08 30 08 90 |
| Web | https://www.bico.com |
Cellink AB Management Efficiency
The company has return on total asset (ROA) of (0.025) % which means that it has lost $0.025 on every $100 spent on assets. This is way below average. Cellink AB's management efficiency ratios could be used to measure how well Cellink AB manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Showing other executives | INSIDER Age | ||
| Fuad Ahmad | IRIDEX | 55 | |
| David MD | Nexalin Technology | 64 | |
| David Meyer | Aurora Spine | N/A | |
| Trent Northcutt | Aurora Spine | 56 | |
| Kenneth CPA | Bluejay Diagnostics | 44 | |
| Aron Tendler | Brainsway | N/A | |
| Pr Zangen | Brainsway | 55 | |
| Richard Areglado | Brainsway | 60 | |
| Laszlo Garamszegi | Aurora Spine | 52 | |
| Leigh Salvo | IRIDEX | N/A | |
| Marilyn Elson | Nexalin Technology | 72 | |
| Brad Nagel | Electromed | N/A | |
| Avner Hagai | Brainsway | 69 | |
| Patrick Mercer | IRIDEX | 52 | |
| Christopher Holland | Electromed | 55 | |
| Christopher Jako | Brainsway | 55 | |
| Mark MD | Bluejay Diagnostics | N/A | |
| Chad Clouse | Aurora Spine | N/A | |
| Yiftach Roth | Brainsway | 54 | |
| Mark Feinberg | Bluejay Diagnostics | N/A | |
| Joel Bradus | Nexalin Technology | N/A | |
Management Performance
| Return On Equity | 0.0068 | |||
| Return On Asset | -0.025 |
Cellink AB Leadership Team
Elected by the shareholders, the Cellink AB's board of directors comprises two types of representatives: Cellink AB inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Cellink. The board's role is to monitor Cellink AB's management team and ensure that shareholders' interests are well served. Cellink AB's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Cellink AB's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Erik Gatenholm, CEO, CoFounder | ||
| Lotta Bus, Gen SVP | ||
| Karin Danielsson, Global Director | ||
| Asa Hillsten, VP Relations | ||
| Itedale Redwan, Chief Bioprinting | ||
| Erica Bell, VP Officer | ||
| Niclas Emanuelsson, Head Operations | ||
| Mikael Engblom, Interim Officer | ||
| Artur Aira, Sr Bioprinting | ||
| Jason Clifton, Head Operations | ||
| Hector Martinez, CoFounder VP |
Cellink Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right pink sheet is not an easy task. Is Cellink AB a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.0068 | |||
| Return On Asset | -0.025 | |||
| Profit Margin | 0.02 % | |||
| Current Valuation | 973.88 M | |||
| Shares Outstanding | 69.07 M | |||
| Shares Owned By Insiders | 38.50 % | |||
| Shares Owned By Institutions | 26.80 % | |||
| Price To Book | 1.23 X | |||
| Price To Sales | 4.61 X | |||
| Revenue | 1.26 B |
Currently Active Assets on Macroaxis
Other Information on Investing in Cellink Pink Sheet
Cellink AB financial ratios help investors to determine whether Cellink Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Cellink with respect to the benefits of owning Cellink AB security.